Carl Zeiss Meditec AG AFX.DE
Composite 52/100; the shares have moved about 45% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 42/100 — a slight mark against it.
Balance-sheet strength ranks 58/100 — a slight point in its favour. Income ranks 56/100 — a slight point in its favour. Valuation ranks 54/100 — a slight point in its favour.
Growth ranks 42/100 — a slight mark against it. Momentum ranks 50/100 — a slight mark against it.
What the company does Carl Zeiss Meditec AG (AFX.DE) designs and manufactures medical technology, focusing on ophthalmology and microsurgery. Its ophthalmology portfolio includes diagnostic devices, surgical microscopes, and laser systems such as the VISUMAX femtosecond laser for vision correction. The microsurgery segment supports minimally invasive treatments with visualization tools and digital workflows like the ZEISS Tumor Workflow.
Key financials Revenue declined -6.4% and EPS fell -57.7% year-over-year. Margins remain tight: gross 51.3%, operating 4.9%, net 4.4%. Profitability metrics are weak: ROE 4.5%, ROA 2.7%. Balance sheet shows moderate leverage (Debt/Equity 0.28) and healthy liquidity (Current ratio 2.43).
Stock health Momentum is mixed: +13.37% over 3 months, +9.47% over 6 months, but -38.67% over 12 months and -39.22% below the 52-week high. RSI(14) is 59.20, indicating neutral momentum. Income pillar scores well at 71.0, but growth and momentum lag at 38.8 and 34.9 respectively.
Price vs fair value The stock trades at a PREMIUM of 62.80% versus our fair-value estimate and a PREMIUM of 5.11% versus the analyst 12-month target. - Trading at a PREMIUM of 62.80% to fair-value estimate (our fair-value estimate 11.18) - Trading at a PREMIUM of 5.11% to analyst target of 28.49 (analyst count 14.0) - Valuation percentile 56.1/100 with Fwd P/E 15.20 and Forward PEG 0.44 - Weak growth (-6.4% revenue, -57.7% EPS) and profitability (ROE 4.5%, ROA 2.7%) - Momentum score 34.9 and 12-month return -38.67%
Looking forward Forward P/E of 15.20 and PEG of 0.44 suggest some valuation support, but weak growth and momentum temper enthusiasm. The dividend yield of 2.0% and payout ratio of 43.8% indicate moderate income appeal. Analysts remain cautiously positioned with a target only 5.11% above current price.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.